相关实验视频

Updated: Jan 11, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

在接受免疫检查点抑制剂治疗的患者中,血液学比,与免疫相关的不良事件和死亡率

Sophie Lekkerkerker^1,2, Karin A H Kaasjager³, Saskia Haitjema⁴

¹Department of Internal Medicine, Sint Antonius Hospital, Nieuwegein, The Netherlands.

|November 12, 2025

概括

治疗前基于炎症的血液学比率,如中性粒细胞与淋巴细胞比率 (NLR),与接受检查点抑制剂的患者的免疫相关不良事件无关. 然而,高比例与增加的死亡风险有关.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
血液学血液学血液学

背景情况:

免疫检查点抑制剂 (ICI) 提高了癌症患者的生存率,但可能导致与免疫相关的不良事件 (irAEs).
与炎症相关的血液学比率与ICI治疗患者的irrAEs或死亡率之间的关联仍然不清楚.

研究的目的:

研究治疗前基于炎症的血液学比率与接受ICI治疗的患者中irrAEs的发生率和死亡率之间的关系.

主要方法:

在2013年至2020年期间,对664名接受ICI治疗的患者进行了回顾性分析.
考克斯回归分析评估了中性粒细胞与淋巴细胞比率 (NLR),血小板与淋巴细胞比率 (PLR),中性粒细胞与淋巴细胞和血小板比率 (NLPR) 以及全身免疫炎症指数 (SII) 与irAEs和死亡率之间的关联.

主要成果:

血液学比率和irAEs之间没有发现显著的关联.
升高的NLR,PLR,NLPR和SII独立地与增加的死亡率有关 (调整后的HR从1.59到2.33不等).

结论:

治疗前的基于炎症的血液学比率不能预测接受ICI的患者的irAEs.
血液学比率升高是该患者群体死亡风险增加的重要预测因素.

更多相关视频

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

相关概念视频

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.